Laurus labs delivers a lackluster performance during FY22; PAT declines 16% yoy

29 Apr 2022 , 12:00 PM

Laurus Labs Limited reported its results for the quarter and financial year ended March 31, 2022.

Company reported revenue of Rs4,936 crore in FY22, up by 3% yoy against FY21. While total net revenue for Q4FY22 increased 1% yoy at Rs1,425 crore.

Its EBITDA for FY22 was reported at Rs1,436 crore, registering a decline of 9% yoy against the previous financial year. For Q4FY22, EBITDA stood at Rs398 crore, down by 17% yoy.

PAT for FY22 declined by 16% yoy at Rs828 crore, and PAT for Q4FY22 dipped 23% yoy at Rs230 crore.

EBITDA margin for Q4FY22 and FY22 came in at 28% and 29% respectively. PAT margins settled at 17% for FY22, and 16% for Q4FY22.

The company declared an interim dividend of Rs1.20 per share.

EPS for Q4FY22 was Rs15.40 per share, and for FY22 was Rs4.30 per share.

The company demonstrated strong mix improvement led by significant progress in the Non-ARV business, especially CDMO-Synthesis which has grown by 77% in FY22 and +105% during Q4.

The company filed 2 product Dossier in Developed markets in Q4 taking total filings to 9 products for FY22.

Laurus Labs is currently trading at Rs572.50 up by Rs0.6 or 0.1% from its previous closing of Rs571.90 on the BSE. The scrip opened at Rs570.25 and has touched intraday high and low of Rs576.65 and Rs555.25 respectively.